Operator: And I show our next question comes from the line of Chris Pasquale from Nephron.
Chris Pasquale: One quick one on PREDICTOR. Just any plans to present that data or disclose the headline results prior to publication?
Tim Herbert: We’ll probably have a presentation down the road. Where we stand today and with the timing of the AASM, which is the SLEEP meeting at June, I don’t think we’re going to be in a position to present there, but we will be looking for a public conference as we work publication in parallel. So we’ll still push for later in the summer or early fall possibly with the AAO ISS meeting, but we will look to get that information out as soon as we can.
Chris Pasquale: And then just circling back to SURMOUNT. When you think about your current patient population, I know if you look at the ADHERE Registry, the average BMI was around 29. Do you think that’s still an accurate reflection of your — the patients you’re treating commercially or since the label expansion has that shifted at all? Just want to draw a distinction between the patients that were in this study at baseline and who you guys are seeing on a day-to-day basis?
Tim Herbert: No, I think good observation. Again, I think the patient in the BMI and the STAR trial is consistent with the BMI that we saw in our 5,000 patient ADHERE Registry. And it reflects patients that have a sleep endoscopy and do not have significant lateral wall collapse, and that’s very consistent with the reports of the SURMOUNT-OSA trial whose the patient started with the BMI at 39. So you would expect those patients to be predominantly lateral wall collapse and as they lose weight, they can relax and expose, the tongue base collapse that — and still effectively treated with Inspire. So I think very, very good consistency from the data that we saw and really look forward to seeing additional data when it comes out, hopefully, this summer.
Operator: And I show our next question comes from the line of Richard Newitter from Truist Securities.
Richard Newitter: Maybe just first on Inspire V. I guess is the anticipated launch timing the same as it was the last time you provided an update? And then just on Inspire V. How are you thinking about or potentially anticipating people, whether it’s physicians or consumers waiting for the Inspire V to come out relative to the existing solution? I guess, is there a risk that there’s a delay in treatment and however transient that might be, is that something that, a, is contemplated in guidance or, b, something you’ve thought about and preparing for.
Tim Herbert: The first — answer to your first question is yes. We are on running our plan and in line with what we talked about at our last earnings call. Number two is with the large — yes, there’s always a risk of patients being aware of it, but we will not be marketing this program until the full launch. And so we believe the risk of warehousing, if you will, or patients waiting for the new technology is going to be very, very low. We have this experience with past products that we’ve had that we haven’t experienced any kind of delay from that perspective. But we’re certainly aware of that. Certainly, we’ll monitor that. But we do not believe that’s going to have a significant impact as patients who have untreated moderate to severe sleep apnea are very motivated to receive therapy.
Richard Newitter: And maybe just one follow-up on the — what you are and aren’t going to provide going forward. So it sounds like you guys are going to continue providing new account openings and utilization for the remainder of ’24, but starting in ’25, you’re no longer going to provide new account openings. And if that’s right, how are you going to help analysts and the investment community understand what the utilization trend is in the business, and what will you provide towards that end?
Tim Herbert: That’s correct. And what we’re going to be focusing on is our top line revenue growth, as well as more importantly profitability going forward, and we’ll continue with discussions with you. But I think the focus is really going to be top line, bottom line reported to be consistent across the industry.
Operator: And I show our next question comes from the line of Shagun Singh from RBC.
Shagun Singh: I was just wondering if you can talk about Inspire V and PREDICTOR study readout. We’ve gotten some pretty good feedback on it and very specifically on Inspire V. I was wondering if you had any take on potential impact in driving down operating times that could potentially increase utilization? And then on the PREDICTOR study, just how meaningful could this be in speeding up that patient funnel? And then just lastly, I was wondering if there’s any update on trends and OSA diagnoses? I think previously you’ve called out a bunch of drivers like GLP-1s, AFIB, DTC. I think there’s general increase in awareness amongst the PCPs, et cetera. So just anything new you’re seeing on the diagnosis front?
Tim Herbert: So with Inspire V, yes, we do expect to have a reduction in operating time, operating room time for the surgeon, specifically because that will remove the pressure sensing lead, which is now going to be incorporated inside the Inspire V neurostimulator. So it’s one less product that the surgeon needs to implant. And so we believe that that’s going to have a significant reduction. We have talked in the past of our average OR time today being between 60 and 90 minutes. And we believe with Inspire V, it could go down to between 45 and 60 minutes. So a significant reduction in the time to perform the procedure. So we think that’s going to be very well accepted, both for the patient as well as the surgeon. Secondly, as far as the patient funnel goes, we know the time for a patient to contact a healthcare provider, go through the diagnostic process and get scheduled and receive Inspire therapy, takes a significant amount of time.
And a key part of it in the middle is to perform the drug induced sleep endoscopy. It could add anywhere from one to three months to the time depending upon the scheduling of that specific surgeon. So we believe with PREDICTOR if we can identify the population of the patients with low BMI that don’t necessarily need to have a sleep endoscopy and can have an alternative review that we can reduce the OR time for those patients. We believe patients with the higher BMIs likely will have to continue with sleep endoscopy, but we’re going to keep working on the data analysis to be able to show that. But hopefully, in a significant number of patients we can show an improvement in the patient experience, meaning the time from contact to receiving therapy.
